Top Emerging Pharma Stocks Compared: Natco Pharma vs Granules India vs Marksans Pharma vs Caplin Point Laboratories vs Alembic Pharmaceuticals on Price, Valuation, Q2 FY27 Results and Risks

Emerging pharma stocks compared here means Natco Pharma, Granules India, Marksans Pharma, Caplin Point Laboratories and Alembic Pharmaceuticals on one page, checked on previous close, market value, valuation and the latest quarterly numbers. The group mixes a complex generics and speciality maker, an active ingredient and dosage maker, a generics maker for regulated markets, an injectables maker for emerging markets and a maker of generics and speciality medicines, so each name earns from a different part of the drug chain, which is exactly why a side-by-side look helps.

Granules India, Marksans Pharma, Caplin Point Laboratories and Alembic Pharmaceuticals have filed their September 2026 quarter, so their results below are Q2 FY27. Natco Pharma has reported only the June 2026 quarter so far. Emerging pharma names follow launches, approvals and export demand, so a glance at the Nifty Pharma page and the Sensex page before you read the tables gives useful backdrop.

Click Here – Get Free Investment Predictions

Emerging Pharma Stocks Compared: Five Drug Makers

The emerging pharma stocks compared here are Natco Pharma, Granules India, Marksans Pharma, Caplin Point Laboratories and Alembic Pharmaceuticals. Granules India is the largest by market capitalisation at Rs 22,937 crore. Previous closes run from Rs 320.00 for Marksans Pharma to Rs 2,386.30 for Caplin Point Laboratories, which is why a side-by-side look at value rather than price is more useful. This emerging pharma stocks compared list is the base for every table that follows.

Stock	Previous close (Rs)	Market cap (Rs crore)
Natco Pharma	808.80	15,866
Granules India	840.50	22,937
Marksans Pharma	320.00	14,471
Caplin Point Laboratories	2,386.30	18,155
Alembic Pharmaceuticals	1,047.25	20,576

A quick look at the business behind each ticker puts the numbers in context. Natco Pharma makes complex generics and speciality medicines for several markets, while Granules India makes active ingredients and finished dosages for global markets. Marksans Pharma makes generic medicines for regulated markets, and Caplin Point Laboratories makes injectables and other medicines for emerging markets. To compare emerging pharma stocks properly, line up price to earnings, return on equity and dividend yield before forming a view.

Rounding out the group, Alembic Pharmaceuticals makes generics, speciality medicines and active ingredients. A fair emerging pharma stock comparison looks at what each company actually earns from, not only at the share price. Complex generics makers, ingredient makers and injectables makers belong in separate mental boxes whenever you compare emerging pharma stocks fairly.

Emerging Pharma Stocks Valuation: Multiples, Returns and Payouts

Natco Pharma trades at the lowest price to earnings ratio in this group at 13.86. Caplin Point Laboratories reports the highest return on equity at 17.88%. Natco Pharma has the lowest price to book value at 1.51. These emerging pharma stocks valuation readings come from the previous close and the latest reported financials. That is the idea behind this emerging pharma stocks compared table: price to earnings and return on equity sit side by side so a high or low reading stands out at once.

Stock	Price to earnings	Price to book	ROE (%)	Dividend yield (%)	Debt to equity
Natco Pharma	13.86	1.51	15.38	0.56	0.08
Granules India	32.14	3.49	10.87	0.19	0.17
Marksans Pharma	25.58	4.34	16.80	0.28	0.14
Caplin Point Laboratories	25.93	4.65	17.88	0.33	0.00
Alembic Pharmaceuticals	24.50	3.46	14.20	1.15	0.26

Emerging pharma names are valued on price to earnings and return on equity, while dividend yield shows how much each pays back. The industry multiple helps you judge whether the market prices a maker for faster growth or steadier earnings. Earnings per share and book value per share are the building blocks behind price to earnings and price to book, so a glance at both in each filing is time well spent. A simple emerging pharma stock comparison like this one is only as useful as the context behind it, which is why dividend yield is worth checking as well.

In this group, price to earnings runs from 13.86 for Natco Pharma to 32.14 for Granules India. Alembic Pharmaceuticals offers the highest dividend yield at 1.15%. The industry price to earnings for this group stands at 40.55, which is the benchmark each stock above can be read against. The industry price to earnings is a handy anchor: a stock above it is priced for faster growth, and one below it is priced for steadier earnings. A well-built emerging pharma stock comparison also notes that launches, approvals and the currency can move results between quarters. Run the same emerging pharma stock comparison on your own watchlist and the pattern in these numbers will be easier to spot. Whenever you compare emerging pharma stocks, note whether a premium is backed by returns or only by size.

Emerging Pharma Stocks Q2 FY27 Results: Revenue and Profit Check

Four of the five emerging pharma stocks compared have filed Q2 FY27 numbers. Alembic Pharmaceuticals posted the fastest revenue growth at 36.6% year on year. Alembic Pharmaceuticals showed the sharpest rise in net profit at 81.8%. Read revenue first and quarterly profit second, since the two together show how much of the growth reaches shareholders. The others are shown on their latest reported quarter, so read each one for what it is. Treat the Q2 FY27 numbers in this emerging pharma stocks compared review as a snapshot of one quarter, not a verdict on any drug maker.

Stock	Q2 FY27 revenue (Rs crore)	Q2 FY26 revenue (Rs crore)	Q2 FY27 net profit (Rs crore)	Q2 FY26 net profit (Rs crore)
Granules India	1,571	1,296	181.8	130.6
Marksans Pharma	958.3	742.0	143.5	99.1
Caplin Point Laboratories	663.1	564.4	182.3	160.2
Alembic Pharmaceuticals	2,619	1,917	333.9	183.7

Natco Pharma Results Snapshot

Natco Pharma has reported only its Q1 FY27 numbers so far, with revenue of Rs 794.4 crore for the June 2026 quarter. Its Q2 FY27 filing is yet to appear, so read the exchange disclosure when it lands before you set it against the others.

Granules India Results Snapshot

Granules India's Q2 FY27 top line stood at Rs 1,571 crore, versus Rs 1,296 crore in Q2 FY26, a rise of 21.2%. Net profit rose 39.2% to Rs 181.8 crore from Rs 130.6 crore. Operating margin expanded to 22.6% from 21.4% a year ago. Earnings per share for the quarter rose to Rs 7.03 from Rs 5.38.

Marksans Pharma Results Snapshot

Marksans Pharma reported Q2 FY27 revenue of Rs 958.3 crore, compared with Rs 742.0 crore a year earlier, a rise of 29.2%. Net profit rose 44.8% to Rs 143.5 crore from Rs 99.1 crore. Operating margin expanded to 24.7% from 23.1% a year ago. Earnings per share for the quarter rose to Rs 3.11 from Rs 2.17.

Caplin Point Laboratories Results Snapshot

In the September 2026 quarter, Caplin Point Laboratories booked revenue of Rs 663.1 crore against Rs 564.4 crore in the same quarter last year, a rise of 17.5%. Net profit rose 13.8% to Rs 182.3 crore from Rs 160.2 crore. Earnings per share for the quarter rose to Rs 23.37 from Rs 20.25.

Alembic Pharmaceuticals Results Snapshot

Alembic Pharmaceuticals' Q2 FY27 top line stood at Rs 2,619 crore, versus Rs 1,917 crore in Q2 FY26, a rise of 36.6%. Net profit rose 81.8% to Rs 333.9 crore from Rs 183.7 crore. Operating margin expanded to 22.2% from 17.0% a year ago. Earnings per share for the quarter rose to Rs 17.05 from Rs 9.40.

Drug maker results depend on product launches, plant approvals, pricing and the currency, so profit can look different from revenue in a single quarter. That is why an emerging pharma stock comparison works best when revenue and profit are read together across two or three quarters. Used this way, an emerging pharma stocks compared review becomes a map of the sector rather than a price list. When you compare emerging pharma stocks after each result season, track how dividend yield changes from one quarter to the next. An emerging pharma stock comparison built on one quarter of data is a starting point, and the next set of results will update it.

Emerging Pharma Stocks Compared Two at a Time: Three Pairings

Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare emerging pharma stocks two at a time.

Natco Pharma vs Alembic Pharmaceuticals

Natco Pharma makes complex generics and speciality medicines, while Alembic Pharmaceuticals makes generics, speciality medicines and active ingredients. On price to earnings, Natco Pharma carries the lower multiple at 13.86 against 24.50 for Alembic Pharmaceuticals. Natco Pharma reports the higher return on equity, at 15.38% against 14.20% for Alembic Pharmaceuticals. For dividend income, Alembic Pharmaceuticals offers 1.15% against 0.56% at Natco Pharma. Both lean on complex products, so read growth next to valuation before you judge either multiple.

Granules India vs Marksans Pharma

Granules India makes active ingredients and finished dosages, while Marksans Pharma makes generics for regulated markets. Marksans Pharma reports the higher return on equity, at 16.80% against 10.87% for Granules India. For dividend income, Marksans Pharma offers 0.28% against 0.19% at Granules India. In Q2 FY27, Marksans Pharma grew revenue faster, at 29.2% year on year against 21.2% for Granules India. Both serve global buyers, so read margins and returns together.

Caplin Point Laboratories vs Granules India

Caplin Point Laboratories makes injectables and other medicines for emerging markets, while Granules India serves global buyers. Granules India is about 1.3 times the size of Caplin Point Laboratories by market capitalisation, at Rs 22,937 crore against Rs 18,155 crore. On price to earnings, Caplin Point Laboratories carries the lower multiple at 25.93 against 32.14 for Granules India. Caplin Point Laboratories reports the higher return on equity, at 17.88% against 10.87% for Granules India. Different end markets are priced differently, so read the business mix before you read the ratio.

Best Emerging Pharma Stocks for Each Type of Investor

If you are asking which of the best emerging pharma stocks here suits you, the answer depends on what you value. The table below shows who leads on each measure today, which is the fairest way to answer without naming a single winner. Any emerging pharma stocks compared table can mislead if you stop at one row, because each drug maker leads on a different measure.

If you care most about	Start your research with	The number
Lowest price to earnings	Natco Pharma	13.86
Highest return on equity	Caplin Point Laboratories	17.88%
Highest dividend yield	Alembic Pharmaceuticals	1.15%
Lowest price to book value	Natco Pharma	1.51
Largest by market capitalisation	Granules India	Rs 22,937 crore
Fastest Q2 FY27 revenue growth	Alembic Pharmaceuticals	36.6%
Sharpest Q2 FY27 net profit rise	Alembic Pharmaceuticals	81.8%

No single name tops every row, which is exactly why an emerging pharma stock comparison helps. Product mix, margins, returns and valuation each point to a different maker, so decide what matters most to you before you rank the numbers.

What Is Driving Demand for Generics, Active Ingredients and Speciality Medicines Right Now?

Generic launches, active ingredient supply and emerging market sales give mid-sized drug makers several routes to grow. Firms with approved plants can serve regulated markets with confidence. Knowing what moves launches and plant approvals helps you compare emerging pharma stocks with the right questions in mind.

Launch timing, plant approvals and product mix decide margins. A rising share of complex products can lift returns for drug makers. A good emerging pharma stocks compared routine therefore tracks launches, approvals and margins.

Risks to Weigh When You Compare Emerging Pharma Stocks

Emerging pharma stocks depend on product launches, regulatory approvals, pricing in export markets and currency moves. Earnings can swing between quarters, so read each filing for launch, margin and approval commentary before you compare them. Every emerging pharma stock comparison has blind spots, and for this group the biggest is launches and plant approvals. A thoughtful emerging pharma stocks compared review keeps these risks next to the numbers instead of in a footnote.

Because launches, approvals and margins drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter. Read together, the risk notes and the tables make this emerging pharma stocks compared guide a balanced starting point.

How to Compare Emerging Pharma Stocks and Build a Shortlist

Start by deciding whether you prefer complex generics, active ingredients or injectables, because each responds to different triggers. Complex generics reward readers who track launches, while ingredient makers reward those who track volumes and plant use. Done step by step, this emerging pharma stocks compared routine becomes repeatable rather than a one-off exercise.

Then check valuation and returns, because premium multiples leave less room for slips in approvals. Spreading your attention across one complex generics name and one ingredient or injectables name is a simple way to see both sides of the sector. Keep the shortlist of best emerging pharma stocks short enough that you can actually follow each company's quarterly results. When you compare emerging pharma stocks again after new results, update only the rows that changed instead of starting over.

The Univest stock screener lets you filter emerging pharma stocks by market capitalisation, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this emerging pharma stocks compared page after the next set of results to see which numbers have moved.

Check the Univest Screener for live emerging pharma stock data

Download the Univest iOS App or Univest Android App to track these emerging pharma stocks live.

Conclusion: Emerging Pharma Stocks Compared at a Glance

This emerging pharma stocks compared review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Granules India leads on size and Caplin Point Laboratories leads on return on equity, while the others bring their own strengths. Treat the emerging pharma stocks Q2 FY27 results and emerging pharma stocks valuation tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare emerging pharma stocks again next quarter, the same checklist of price to earnings, return on equity and dividend yield will work.

Frequently Asked Questions on Emerging Pharma Stocks Compared

Which are the top emerging pharma stocks compared in this article?

Ans. The emerging pharma stocks compared in this article are Natco Pharma, Granules India, Marksans Pharma, Caplin Point Laboratories and Alembic Pharmaceuticals. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, so you get a clear side-by-side starting point before you open any single company's filings in more depth.

Which emerging pharma stock has the highest market capitalisation?

Ans. Among the five names, Granules India has the highest market capitalisation at Rs 22,937 crore. Alembic Pharmaceuticals follows at Rs 20,576 crore. Market capitalisation is the total value the market places on a company and moves with the share price every day, so check the live figure before you rely on it.

Which of these emerging pharma stocks has the lowest price to earnings ratio?

Ans. On emerging pharma stocks valuation, Natco Pharma has the lowest price to earnings ratio among these emerging pharma stocks at 13.86, based on the latest reported earnings. Granules India sits at the other end at 32.14. A lower multiple is not automatically better, since growth, margins and business quality all influence what investors are willing to pay.

Which emerging pharma stock has the highest return on equity?

Ans. Caplin Point Laboratories reports the highest return on equity in this group at 17.88%. Return on equity shows how much profit a company earns on shareholder funds, so a higher figure usually points to efficient use of capital. Compare it over several years, and keep debt levels in mind, because heavy borrowing can lift the ratio.

How did emerging pharma stocks perform in Q2 FY27 results?

Ans. Four of the five names have filed Q2 FY27 numbers in our data. Alembic Pharmaceuticals recorded the fastest revenue growth at 36.6% year on year. Alembic Pharmaceuticals showed the sharpest net profit rise at 81.8%. For emerging pharma stocks Q2 FY27 results, the others are covered on their latest reported quarter, and each filing on the exchange website carries the full detail.

What are the main risks when you compare emerging pharma stocks?

Ans. Emerging pharma stocks depend on product launches, regulatory approvals, pricing in export markets and currency moves. Earnings can swing between quarters, so read each filing for launch, margin and approval commentary before you compare them. Keep an eye on launches, approvals and margins.

Which metrics matter most when you compare emerging pharma stocks?

Ans. Launches, operating margin, return on equity and plant approvals matter most for operating performance. Price to earnings and dividend yield show how the market values each maker. Read each company's filing for these along with the numbers in this article.

Which is the best emerging pharma stock to buy among these five?

Ans. The best emerging pharma stock depends on whether you value complex generics, active ingredients or injectables, because the five names differ on all of these. On the numbers in this article, Granules India has the largest market capitalisation; Natco Pharma has the lowest price to earnings; Caplin Point Laboratories has the highest return on equity; Alembic Pharmaceuticals has the highest dividend yield. No single stock tops every measure, and none of this is a recommendation. Use the tables to build a shortlist, check the latest filings, and speak to a SEBI-registered advisor before you decide, since your goals, time horizon and risk appetite matter more than any ranking.